Disaster recovery port in a portable computer
    81.
    发明授权
    Disaster recovery port in a portable computer 有权
    便携式计算机中的灾难恢复端口

    公开(公告)号:US06973588B2

    公开(公告)日:2005-12-06

    申请号:US10306527

    申请日:2002-11-27

    CPC classification number: G06F1/1632 G06F1/1626 G06F1/1684 G06F2200/1632

    Abstract: An architecture for updating corrupted instructions in a computing device. The computing device includes a housing for enclosing a flash memory for storing a boot loader routine, and at least one boundary-scan device internal to the computing device for processing the boot loader routine, and operatively disposed on a boundary-scan bus. The housing includes a boundary-scan port through which updated instructions are communicated and power provided. The port is concealed under a label, cover, or in a location that limits access by the device owner, such as the battery well.

    Abstract translation: 用于更新计算设备中的损坏指令的架构。 计算设备包括用于封装用于存储引导加载程序的闪存的外壳,以及用于处理引导加载程序的计算设备内部的至少一个边界扫描设备,并且可操作地设置在边界扫描总线上。 外壳包括边界扫描端口,通过该边界扫描端口更新了指令并提供了电源。 该端口被隐藏在标签,盖子或限制设备所有者访问的位置,例如电池井。

    Digital media system with request-based merging of metadata from multiple databases
    82.
    发明申请
    Digital media system with request-based merging of metadata from multiple databases 审中-公开
    数字媒体系统,具有来自多个数据库的元数据的基于请求的合并

    公开(公告)号:US20050065912A1

    公开(公告)日:2005-03-24

    申请号:US10653307

    申请日:2003-09-02

    Abstract: A digital media system includes a changer control system that controls an optical disc changer. The changer control system includes a local database of metadata records containing information regarding the optical discs in the optical disc changer. The changer control system is also networked to a digital media server that stores digital media files. The digital media server includes a remote database of metadata records containing information regarding the digital media files. The changer control system provides a user interface that allows a user to access information regarding both the optical discs in the optical disc changer and the digital media files stored in the digital media server. To provide this information, a file system of the changer control system creates a merged set of selected metadata records from the local database and the remote database, in response to a request from the user interface.

    Abstract translation: 数字媒体系统包括控制光盘更换器的变换器控制系统。 更换器控制系统包括包含关于光盘更换器中的光盘的信息的元数据记录的本地数据库。 更换器控制系统还与存储数字媒体文件的数字媒体服务器联网。 数字媒体服务器包括元数据记录的远程数据库,其中包含有关数字媒体文件的信息。 更换器控制系统提供用户界面,其允许用户访问关于光盘更换器中的光盘和存储在数字媒体服务器中的数字媒体文件的信息。 为了提供该信息,更改器控制系统的文件系统响应于来自用户界面的请求,从本地数据库和远程数据库创建合并的一组选定的元数据记录。

    Methods for treating ischemic disorders using carbon monoxide
    83.
    发明申请
    Methods for treating ischemic disorders using carbon monoxide 有权
    使用一氧化碳治疗缺血性疾病的方法

    公开(公告)号:US20050048133A1

    公开(公告)日:2005-03-03

    申请号:US10679135

    申请日:2003-10-03

    Abstract: The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

    Abstract translation: 本发明提供了一种治疗受试者的缺血性疾病的方法,其包括在足够的时间内以足够量的时间向所述受试者施用药学上可接受的形式的选择素拮抗剂,以防止白血细胞积聚,从而治疗缺血性 主题无序。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法,其包括在足够的时间内向受试者施用足够量的一氧化碳气体,从而治疗受试者的缺血性疾病。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法,其包括在足够的时间内以足够的时间向受试者施用药学上可接受的形式的灭活因子IX以抑制凝血,以便治疗缺血性障碍 学科。

    Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof
    85.
    发明授权
    Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof 失效
    细胞外新型RAGE结合蛋白(EN-RAGE)及其用途

    公开(公告)号:US06670136B2

    公开(公告)日:2003-12-30

    申请号:US09826589

    申请日:2001-04-05

    CPC classification number: C07K14/70503 A01K2217/05 A61K38/00

    Abstract: The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

    Abstract translation: 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法,其包括:(a)混合:(i)RAGE肽或sRAGE肽或 片段,(ii)EN-RAGE肽或其片段,和(iii)化合物; (b)测量步骤(a)(i)的肽与步骤(a)(ii)的肽之间的相互作用水平,和(c)将步骤(b)中所发生的相互作用的量与测量的量进行比较 在不存在化合物的情况下,步骤(a)(i)的petpide和步骤(a)(ii)的肽之间,从而确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用 其中在化合物存在下相互作用量的减少表明该化合物能够抑制相互作用。 本发明还提供了一种抑制受试者的炎症的方法,其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物(RAGE)的相互作用,从而抑制受试者的炎症 学科。

    High performance substrate scanning

    公开(公告)号:US06586750B2

    公开(公告)日:2003-07-01

    申请号:US09922492

    申请日:2001-08-03

    CPC classification number: G01N21/6452 G01N21/6456

    Abstract: An optical scanning system for examining material associated with a substrate includes at least one scanning module for displacing two or more objective lenses, at least one optical coupling system and a translation system. The two objective lenses are mounted on one or more scan arms and are constructed to scan over regions or subregions associated with the substrate. The scanning module is configured to displace the scan arm(s) to perform the scan and thereby displace the two objective lenses. Each objective lens is arranged to deliver light to the material and collect light from the material.

    Nucleic acid encoding bovine extracellular rage binding protein (en-rage)
    87.
    发明授权
    Nucleic acid encoding bovine extracellular rage binding protein (en-rage) 失效
    编码牛细胞外rage结合蛋白的核酸(en-rage)

    公开(公告)号:US06555340B1

    公开(公告)日:2003-04-29

    申请号:US09263312

    申请日:1999-03-05

    CPC classification number: A61K38/1703 A01K2217/05 C07K14/70503

    Abstract: The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.

    Abstract translation: 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法。 本发明还提供了一种抑制受试者的炎症的方法,其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物(RAGE)的相互作用,从而抑制受试者的炎症 学科。

    Methods involving direct write optical lithography
    88.
    发明授权
    Methods involving direct write optical lithography 失效
    包括直写光刻技术的组成和方法

    公开(公告)号:US06480324B2

    公开(公告)日:2002-11-12

    申请号:US09880058

    申请日:2001-06-14

    Abstract: An improved optical photolithography system and method provides predetermined light patterns generated by a direct write system without the use of photomasks. The Direct Write System provides predetermined light patterns projected on the surface of a substrate (e.g., a wafer) by using a computer controlled component for dynamically generating the predetermined light pattern, e.g., a spatial light modulator. Image patterns are stored in a computer and through electronic control of the spatial light modulator directly illuminate the wafer to define a portion of the polymer array, rather than being defined by a pattern on a photomask. Thus, in the Direct Write System each pixel is illuminated with an optical beam of suitable intensity and the imaging (printing) of an individual feature is determined by computer control of the spatial light modulator at each photolithographic step without the use of a photomask. The Direct Write System including a spatial light modulator is particularly useful in the synthesis of DNA arrays and provides an efficient element for polymer array synthesis by using spatial light modulators to generate a predetermined light pattern that defines the image patterns of a polymer array to be deprotected.

    Abstract translation: 改进的光学光刻系统和方法提供由直接写入系统产生的预定光图案,而不使用光掩模。 直接写入系统通过使用用于动态生成预定光图案的计算机控制部件(例如空间光调制器)来提供投影在基板(例如,晶片)的表面上的预定光图案。 图像图案存储在计算机中,并且通过空间光调制器的电子控制直接照亮晶片以限定聚合物阵列的一部分,而不是由光掩模上的图案限定。 因此,在直写系统中,每个像素用适当强度的光束照射,并且通过在每个光刻步骤的计算机控制空间光调制器而不使用光掩模来确定单个特征的成像(打印)。 包括空间光调制器在内的直接写入系统在DNA阵列的合成中特别有用,并且通过使用空间光调制器产生限定要去保护的聚合物阵列的图像图案的预定光图案,为聚合物阵列合成提供有效元素 。

    Endotoxin-induced thrombosis factor which induces procoagulant activity
in endothelial cells
    90.
    发明授权
    Endotoxin-induced thrombosis factor which induces procoagulant activity in endothelial cells 失效
    在内皮细胞中诱导程序性活化的内毒素诱导的血栓形成因子

    公开(公告)号:US5227368A

    公开(公告)日:1993-07-13

    申请号:US486311

    申请日:1990-02-28

    CPC classification number: C07K16/24 C07K14/52 A61K38/00

    Abstract: This invention provides a purified endotoxin-induced thrombosis factor, preferably an endotoxin-induced thrombosis factor characterized by an apparent molecular weight between about 50,000 and 65,000 daltons, more specifically about 55,000 daltons, on reduced and nonreduced SDS-polyacrylamide gels, by maximal recovery on elution from such gels at 52,000 to 58,000 daltons, by the ability to migrate as a single band on such gels, by the ability to precipitate in ammonium sulfate at saturations from 40% to 70%, by the ability to precipitate in polyethylene glycol at concentrations above 15%, by high hydrophobicity, by the ability to bind weakly to a hydroxylapatite column and to a lentil lectin column, by the ability to bind tightly to a hydrophobic interaction resin and smear off with ethylene glycol, and by the ability to bind tightly to a reverse-phase column and elute more effectively with isopropranol than with acetonitrile, by the ability to bind to an anion exchange resin over a pH range from 5 to 10, by the inability to bind to a cation exchange resin, by resistance to acid denaturation up to 30 minutes, resistance to polymyxin, sensitivity to heating at 95.degree. C. for 30 minutes, and sensitivity to trypsin exposure for 24 hours. Another characteristic of a purified endotoxin-induced thrombosis factor that it maximally induces tissue factor after six to eight hours, and continues to induce tissue factor for up to sixty hours. This invention also provides purified nucleic acid molecules, antibodies, an inhibitor, an antagonist, pharmaceutical compositions, methods of treatment, and methods of preparation all directed to endotoxin-induced thrombosis factor.

    Abstract translation: 本发明提供纯化的内毒素诱导的血栓形成因子,优选内毒素诱导的血栓形成因子,其特征在于在还原和非还原的SDS-聚丙烯酰胺凝胶上的表观分子量在约50,000和65,000道尔顿之间,更具体地约55,000道尔顿,通过 通过在这种凝胶上作为单条带迁移的能力,通过在40%至70%的饱和度下在硫酸铵中沉淀的能力,通过在聚乙二醇中沉淀的能力,从这种凝胶中洗脱52,000至58,000道尔顿 15%以上,疏水性高,通过与羟基磷灰石柱和扁豆凝集素柱弱结合的能力,通过与疏水相互作用树脂紧密结合并用乙二醇去除的能力,以及紧密结合的能力 到反相柱,并且用异丙醇比乙腈更有效地洗脱,通过在pH下结合阴离子交换树脂的能力 通过不能与阳离子交换树脂结合,通过耐酸性变性达30分钟,耐多粘菌素,对95℃加热30分钟的敏感性和对胰蛋白酶暴露的灵敏度为24,范围为5至10 小时。 纯化的内毒素诱导的血栓形成因子的另一个特征是其在6至8小时后最大程度地诱导组织因子,并继续诱导组织因子长达六十小时。 本发明还提供纯化的核酸分子,抗体,抑制剂,拮抗剂,药物组合物,治疗方法以及针对内毒素诱导的血栓形成因子的全部制备方法。

Patent Agency Ranking